Results 241 to 250 of about 120,218 (287)

Mucous Membrane Pemphigoid After Anti‐PD‐1 Therapy: Risk‐Stratified Management and Treatment Outcomes

International Journal of Dermatology, EarlyView.
ABSTRACT Mucous membrane pemphigoid (MMP) following anti‐programmed cell death‐1 (PD‐1) therapy is rare but increasingly reported. Management of high‐ and low‐risk MMP in this setting and the potential oncologic trade‐offs remain poorly defined. We performed a narrative synthesis of all published cases of anti‐PD‐1‐associated MMP, following MEDLINE ...
Serena Dienes, Negar Esfandiari, Steven Daveluy   +2 more
wiley   +1 more source

First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancer. [PDF]

Oncologist
Nasca V, Tinè G, Taieb J, Lonardi S, Boursi B, Margalit O, Salvatore L, Cohen R, Ros J, Ambrosini M, Zwart K, Roodhart J, Jayachandran P, Overman MJ, Elez ME, Cremolini C, Tougeron D, Koopman M, André T, Miceli R, Pietrantonio F.   +20 more
europepmc   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

Checkpoint Inhibitor-Associated Myasthenia-Myositis Overlap With Neuromuscular Respiratory Failure After Dual PD-L1 Plus CTLA-4 Checkpoint Blockade for Hepatocellular Carcinoma. [PDF]

Cureus
Bowen AM, Baraka D, Thulluri R, Lantis M, Russell C, Patterson T, Pierce S, Alshaikhli A.   +7 more
europepmc   +1 more source

Latent Neoehrlichia mikurensis Infections May Be Reactivated in Patients With B‐Cell Lymphomas Treated With Rituximab

Immunology, EarlyView.
Eight percent of this cohort of patients had a latent Neoehrlichia mikurensis infection. It was only the latently infected patients who had N. mikurensis‐specific T cells, not the matched B‐cell lymphoma patients without the infection. The T‐cell responses of latently infected patients included perforin‐expressing Th1 and CD8+ T cells that upregulated ...
Linda Wass, Catharina Lewerin, Daniel Jaén‐Luchoro, Christine Lingblom, Christine Wennerås   +4 more
wiley   +1 more source

ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation. [PDF]

J Immunother Cancer
Hayashi H, Tatsumi K, Katada H, Matsuda Y, Tsunenari T, Honda M, Nemoto T, Shimizu S, Miura-Okuda M, Ikuta Y, Ito A, Ogami C, Kato C, Kamimura M, Kibayashi T, Kubo C, Komatsu S, Komori Y, Shinozuka J, Susumu H, Tanno H, Tomii Y, Nakagawa K, Nagano H, Nanami M, Nishito Y, Fujisawa N, Matsushita T, Michisaka S, Yamazaki M, Yoshimoto M, Wakatsuki H, Wakabayashi T, Wada NA, Ueda O, Konishi H, Kashima K, Tanaka H, Endo M, Kitazawa T, Sakaguchi S, Kamata-Sakurai M, Igawa T.   +42 more
europepmc   +1 more source

Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas

Journal of the European Academy of Dermatology and Venereology, EarlyView.
When questioning the effectiveness of adjuvant immunotherapy for acral melanomas, we found no clinical benefit to the adjuvant proposal, despite the maintenance of adverse effects. Abstract Background Solar factors play no role in the development of acral melanoma (AM). AM is characterized by low cumulative solar damage (low CSD).
Damien Sanogo, Romain Levard, Julie Cassecuel, Amir Khammari, Gaelle Quereux, Florent Grange, Henri Montaudié, Florence Brunet‐Possenti, Justine Lavaud, Marie‐Thérèse Leccia, Géraldine Jeudy, Anne Dompmartin, Brigitte Dreno, Jean‐Matthieu L’Orphelin   +13 more
wiley   +1 more source

Impact of steroid dose and timing on efficacy of combination PD-1/CTLA-4 blockade. [PDF]

Oncoimmunology
Curkovic NB, Irlmeier R, Bai X, Cui C, Ye F, Burnette HR, Lawless AR, Czapla JA, Sullivan R, Johnson DB.   +9 more
europepmc   +1 more source

No Evidence of Microsatellite Instability in Head and Neck Squamous Cell Carcinoma of Non‐Smokers and Non‐Drinkers

Journal of Oral Pathology &Medicine, EarlyView.
ABSTRACT Introduction While the prevalence of microsatellite instability (MSI) is low in the whole head and neck squamous cell carcinoma (HNSCC) population, it has been suggested to be more prominent in tumors of non‐smokers. Therefore, the goal of this study was to determine the presence of MSI in a cohort of well‐defined HNSCC of non‐smokers and non ...
F. J. Mulder, T. F. B. Gielgens, E. J. de Ruiter, R. de Bree, M. F. C. M. van den Hout, B. Kremer, S. M. Willems, E. J. M. Speel   +7 more
wiley   +1 more source

The effect of HLA genotype on disease onset and severity in CTLA-4 insufficiency. [PDF]

Front Immunol
Posadas-Cantera S, Mitsuiki N, Emmerich F, Patiño V, Lorenz HM, Neth O, Dybedal I, Taskén K, Schäffer AA, Grimbacher B, Gámez-Díaz L.   +10 more
europepmc   +1 more source